Skip to main content
SpringerLink
Log in

Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the prognostic significance of international prognostic index (IPI), mantle cell lymphoma IPI (MIPI), simplified MIPI (sMIPI), and MIPI biological (MIPIb), as well as their correlation with immunophenotype, clinical characteristics, and overall survival (OS), in a selected group of 54 patients with advanced-stage mantle cell lymphoma (MCL), treated uniformly with CHOP. Seventeen patients had IV clinical stage (CS), while other 37 had leukemic phase at presentation. Diffuse type of marrow infiltration was verified in 68.5% and nodular in remainder patients. Extranodal localization (25.9%) included bowel (20.4%), pleural effusion, sinus, and palpebral infiltration. All of analyzed patients expressed typical MCL immunophenotypic profile: CD19+CD20+CD22+CD5+Cyclin-D1+FMC7+CD79b+smIg+CD38+/−CD23−CD10−. Median OS of the whole group was 23 months, without significant differences between IV CS and leukemic phase patients. Thirty-two patients (59.3%) responded to initial treatment, 9 (16.7%) with complete and 23 (42.6%) with partial remission. Negative prognostic influence on OS had high IPI (P < 0.01), high sMIPI (P < 0.001), MIPI (P < 0.01), MIPIb (P < 0.01), extranodal localization (P < 0.01), and diffuse marrow infiltration (P < 0.01). Testing between randomly selected groups showed that patients with lower proportion of CD5+ cells (<80%) correlated with cytological blastoid variant and had shorter survival comparing with the group with higher proportion of CD5+ cells (>80%) (P < 0.01). Using univariate Cox regression, we proved that IPI, sMIPI, MIPI, and MIPIb had an independent predictive importance (P < 0.01) for OS in uniformly treated advanced MCL patients, although sMIPI prognostic significance was the highest (P < 0.001).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Harris NL, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.

    PubMed  CAS  Google Scholar 

  2. Raffeld M, Jaffe ES. Bcl–1, t (11; 14), and mantle cell-derived lymphomas. Blood. 1991;78:259–63.

    PubMed  CAS  Google Scholar 

  3. Matutes E, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leukemia Lymphoma. 2004;45:2007–15.

    Article  PubMed  CAS  Google Scholar 

  4. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115–27.

    PubMed  CAS  Google Scholar 

  5. Weisenburger DD, Armitage JO. Mantle cell lymphoma; an entity comes of age. Blood. 1996;87:4483–94.

    PubMed  CAS  Google Scholar 

  6. Shipp M, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  7. Hoster E, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  PubMed  CAS  Google Scholar 

  8. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877–95.

    PubMed  CAS  Google Scholar 

  9. Wood BL, et al. 2006 Bethesda international consensus recommendation on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: oprimal reagents and reporting for the flow cytometric diagnosis of hematopoietic heoplasia. Cytom Part B (Clin Cytom). 2007;72B:14–22.

    Article  Google Scholar 

  10. Boyum A, et al. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21:77–89.

    Article  CAS  Google Scholar 

  11. Moreau EJ, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Hematopathology. 1997;108:378–82.

    CAS  Google Scholar 

  12. Matutes E, Attygalle A, Wotherspoon A, Catovsky D. Diagnostic issues in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Hematol. 2010;23:3–20.

    Article  CAS  Google Scholar 

  13. Foran JM, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117–21.

    Article  PubMed  Google Scholar 

  14. Ghielmini M, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–11.

    Article  PubMed  CAS  Google Scholar 

  15. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114:1469–76.

    Article  PubMed  CAS  Google Scholar 

  16. Howard OM, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288–94.

    Article  PubMed  CAS  Google Scholar 

  17. Schulz H, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–14.

    Article  PubMed  CAS  Google Scholar 

  18. Geisler CH, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530–3.

    Article  PubMed  CAS  Google Scholar 

  19. Determann O, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385–7.

    Article  PubMed  CAS  Google Scholar 

  20. Katzenberger T, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.

    Article  PubMed  CAS  Google Scholar 

  21. Schrader C, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93:939–45.

    Article  PubMed  CAS  Google Scholar 

  22. Schrader C, et al. Repp 86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol. 2005;75:498–504.

    Article  PubMed  CAS  Google Scholar 

  23. Schrader C, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18:1200–6.

    Article  PubMed  CAS  Google Scholar 

  24. Tiemann M, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29–38.

    Article  PubMed  Google Scholar 

  25. Schaffel R, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21:133–9.

    Article  PubMed  CAS  Google Scholar 

  26. Räty R, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002;69:11–20.

    Article  PubMed  Google Scholar 

  27. Wohlschlaeger CH, Lange HM, Feller AC. Aberrant immunophenotypes of mantle cell lymphomas. Leukemia Lymphoma. 2003;44:269–73.

    Article  PubMed  Google Scholar 

  28. Sriganeshan V, Blom TR, Weissmann DJ. A unique case of mantle cell lymphoma with an aberrant CD5/CD10 immunophenotype and typical morphology. Arch Pathol Lab Med. 2008;132:1346–9.

    PubMed  Google Scholar 

  29. Rummel MJ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–9.

    Article  PubMed  CAS  Google Scholar 

  30. O’Connor OA, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–84.

    Article  PubMed  Google Scholar 

  31. Fisher RI, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.

    Article  PubMed  Google Scholar 

  32. Witzig TE, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–456.

    Article  PubMed  CAS  Google Scholar 

  33. Wiernik PH, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.

    Article  PubMed  Google Scholar 

  34. Todorovic M, et al. Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma. Med Oncol. 2007;24:413–8.

    Article  PubMed  CAS  Google Scholar 

  35. Salar A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274–80.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported from the Ministry of Science of Serbia (Project No 41004).

Author information

Authors and Affiliations

  1. Clinic of Hematology, Clinical Center of Serbia, 11000, Belgrade, Serbia

    Milena Todorovic, Bosko Andjelic, Nada Kraguljac Kurtovic & Biljana Mihaljevic

  2. Faculty of Medicine, University of Belgrade, Belgrade, Serbia

    Milena Todorovic, Dejana Stanisavljevic & Biljana Mihaljevic

  3. Institute for Medical Research, University of Belgrade, Belgrade, Serbia

    Bela Balint

  4. Institute of Transfusiology, Military Medical Academy, Belgrade, Serbia

    Bela Balint

  5. Institute for Medical Statistics and Informatics, Belgrade, Serbia

    Dejana Stanisavljevic

  6. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Ziv Radisavljevic

Authors
  1. Milena Todorovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bela Balint
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bosko Andjelic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dejana Stanisavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nada Kraguljac Kurtovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ziv Radisavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Biljana Mihaljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milena Todorovic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Todorovic, M., Balint, B., Andjelic, B. et al. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. Med Oncol 29, 2212–2219 (2012). https://doi.org/10.1007/s12032-011-0136-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0136-1

Keywords

Search

Navigation